Zhejiang Garden Biopharmaceutical Co (300401) Fair Value & Analysis
Healthcare · CN · Market cap 8.5B CNY
Analysis
Zhejiang Garden Biopharmaceutical Co (300401) currently trades at ¥19.87, while our model-based Fair Value estimate is ¥11.65 — implying the stock looks roughly 41.4% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
About the company
Zhejiang Garden Biopharmaceutical Co.,Ltd. engages in the research, development, production and sales of vitamin products and pharmaceuticals in China. The company offers lanolin cholesterol series products, such as cholesterol and feed grade cholesterol; vitamin D3 products, including food additives compound nutrient fortifier SDS, food additives compound nutritional fortifier CO and MO, cholecalciferol, vitamin D3 particles, feed additive vitamin D3 oil, and VD3 resin oil; and 25 HydroxyVitamin D3 Progen, 25 hydroxyvitamin D3, and 25 hydroxyvitamin D3 powder. It also provides refined lanolin comprising anhydrous lanolin, wool oil, wool wax, low chroma ultra pure fat, lanolin alcohol, isopropyl lanolate, lanolinic acid, high acid fat, and wool acid biofuel/wool alcohol biofuel; and vitamin D3 environmental rodenticide. Zhejiang Garden Biopharmaceutical Co.,Ltd. was formerly known as Zhejiang Garden Bio-chemical High-tech Co., Ltd. and changed its name to Zhejiang Garden Biopharmace…
Open the full interactive analysis →
Similar stocks
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.